Shire PLC: A significant relief for Shire and Lialda in the US

BUY, Fair Value  2160p (+12%)

News published on May Friday 10, 2013
Share on

Yesterday Shire won a patent litigation case against Watson concerning its drug Lialda in a US District Court. This means that the generic of the drug will not be able to launch before June 2020. As Watson is likely to be first-to-file, it should then prevent anyone else from launching a copy of the drug. To make to short, it is protecting the drug - which represents 9% of total sales - for another 7 years. After Shire settled with Actavis on Intuniv, the news is increasing significantly the visibility over patent challenges. Unfortunately, the underlying business is getting more difficult at the same time.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities